Category - Markets

Markets

Maxim transfers coverage of Cardiff Oncology at buy; PT $20

Maxim Group transferred coverage of Cardiff Oncology (NASDAQ:CRDF) to analyst Naureen Quibria, Ph.D., with a “buy” rating and $20 price target. The stock closed at $5.76 on Aug. 6. Cardiff’s PLK inhibitor, onvansertib...

August 9, 2021

Markets

HCW ups BeyondSpring to buy from neutral; PT $100

H.C. Wainwright upgraded BeyondSpring (NASDAQ:BYSI) to “buy” from “neutral” with a price target of $100 after the company reported positive topline results from its DUBLIN-3 registrational trial of plinabulin in...

August 4, 2021

Markets

Ladenburg starts Immutep at buy; PT $8.30

Ladenburg Thalmann launched coverage of Immutep of Australia (NASDAQ:IMMP) with a “buy” rating and $8.30. The stock closed at $3.46 0n Aug. 2. Immutep is a clinical-stage immuno-oncology company focused on developing...

August 3, 2021

Markets

111 Inc. named to top 10 leaders of China’s new pharma retail industry

111 Inc. (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, was named as one of the top 10 leaders of China’s new...

July 30, 2021

Markets

BTIG cuts Misonix to neutral on proposed acquisition by Bioventus

BTIG downgraded Misonix (NASDAQ:MSON) to “neutral” on a pending acquisition by Bioventus. Under the accord, Misonix shareholders would receive either 1.6839 shares of Bioventus common stock or $28 for each share held...

July 30, 2021

Markets

Cantor halves Ardelyx PT to $7 from $14; maintains OW rating

Cantor Fitzgerald slashed its price target for Ardelyx (NASDAQ:ARDX) to $7 from $14 after the company received a complete response letter from the FDA for its NDA for tenapanor to control serum phosphorus in adult...

July 30, 2021

Markets

Cantor starts Nyxoah at OW; PT $43

Cantor Fitzgerald initiated coverage of Nyxoah SA (NASDAQ:NYXH) with an “overweight” rating and 12-month price target of $43, citing the company’s “pipeline and uniquely differentiated product”. The stock closed at $32...

July 28, 2021

Markets

Canaccord starts CVRx at buy; PT $30

Canaccord Genuity initiated coverage of CVRx (NASDAQ:CVRX) with a “buy” rating and price target of $30. The stock closed at $20.22 on July 23. “We believe that CVRx is uniquely positioned in addressing significant unmet...

July 26, 2021

Markets

Stifel starts Acumen Pharma at buy; PT $27

Stifel launched coverage of Acumen Pharmaceuticals (NASDAQ:ABOS) with a “buy” rating and $27 price target. The stock closed at $17.08 on July 23. Acumen is a biotechnology company focused on the development of a next...

July 26, 2021

Markets

Cantor starts SELLAS Life Sciences at OW; PT $18

Cantor Fitzgerald launched coverage of SELLAS Life Sciences (NASDAQ:SLS) with an “outperform” rating and $18 price target. The stock closed at $8.60 on July 20. SELLAS is a late-stage immune-oncology company that is...

July 21, 2021

Category - Markets

Subscribe